TGOM FROM CODE TO CURE® THE TIGIT PATHWAY PVRIG, a Novel Pathway Member Ta r g e t s f o r C a n c e r I m m u n o t h e r a p y : A D e e p D i v e E r a n O p h i r, V P R e s e a r c h & D r u g D i s c o v e r y J u n e 2021 T h e D N A M-1 A x i s • DNAM-1 axis plays an essential role in tumor immunology • PVRIG binds PVRL2 as a functional ligand (TIGIT has a low affinity for PVRL2) 中 • DNAM-1 axis – two parallel dominant complementary inhibitory pathways (PVRIG & TIGIT/CD96?) • TIGIT and PVRIG deliver ...

Compugen Ltd. (NASDAQ:CGEN) Q1 2021 Earnings Conference Call May 13, 2021 8:30 AM ET | --- | |------------------------------------------------------------------------| | | | Company Participants | | Anat Cohen-Dayag - CEO | | Ari Krashin - CFO and COO | | Henry Adewoye - Chief Medical Officer | | Conference Call Participants | | Mark Breidenbach - Oppenheimer Stephen Willey - Stifel | | Daina Graybosch - SVB Leerink | | | | Ren Benjamin - JMP Securities Asthika Goonewardene - Truist Securities | | | | Roger ...

Financial Data and Key Metrics Changes - Revenue for Q4 and full year 2020 was $2 million, marking the first development milestone from the license agreement with AstraZeneca [86] - Research and development expenses for the full year 2020 were $22.8 million, a 15% increase from $19.8 million in 2019, with Q4 expenses at $8.1 million, an 88% increase from $4.3 million in the prior year [87] - Net loss for the full year 2020 was $29.7 million or $0.37 per share, compared to a net loss of $27.3 million or $0.43 per share in 2019 [88] - Cash and cash-related accounts as of December 31, 2020, were approximately $124 million, up from $44 million at the end of the previous year [90] Business Line Data and Key Metrics Changes - The company is executing a comprehensive clinical development program for its anti-PVRIG and TIGIT assets, focusing on the DNAM axis signaling pathways [6][28] - The combination arm of the Phase 1 study of COM701 with nivolumab showed a disease control rate of approximately 67% [10][58] - In the COM701 monotherapy cohort expansion, 30% of patients had stable disease, with a disease control rate of 47% across the study [75] Market Data and Key Metrics Changes - The company is expanding its collaboration with Bristol-Myers Squibb (BMS) to include a Phase 1b cohort expansion study evaluating COM701 with nivolumab [12][31] - The upcoming studies will target various tumor types, including ovarian, breast, endometrial, and microsatellite stable colorectal cancer [15][31] Company Strategy and Development Direction - The company aims to maintain its leadership position in the DNAM axis immunotherapy space by advancing its clinical programs and exploring combination therapies [28][29] - The strategy includes evaluating the dual blockade of PVRIG with PD1 or TIGIT and triple blockade with PD1 and TIGIT [25][81] - The company is also focusing on early-stage pipeline programs targeting the immunosuppressive tumor microenvironment [45] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of PVRIG and TIGIT as new immunotherapy targets, highlighting the growing interest in these pathways within the biopharma industry [27][29] - The company remains optimistic about its clinical data and the potential for COM701 to provide meaningful clinical benefits in heavily pre-treated patient populations [78] Other Important Information - The company has received multiple patents to protect its pipeline candidates, including COM701 and COM902 [46] - The ongoing COVID-19 pandemic has not significantly impacted the company's activities, with enrollment and data collection remaining on track [51] Q&A Session Summary Question: Differences in Efficacy Between Monotherapy and Combination Arms - Management noted that the monotherapy expansion cohort's primary objective was to establish safety and tolerability, while the combination arm showed preliminary antitumor activity [94][96] Question: Insights on Complete Response at Low Dosage - Management explained that the complete response observed at a low dosage may be due to the time required for COM701 to inhibit cancer cell activity, especially in previously treated patients [101][102] Question: Biomarker Strategy for Patient Selection - The company plans to evaluate pre- and post-treatment samples to correlate biomarkers with antitumor activity, focusing on the DNAM axis [103][111] Question: Kinetics of Complete Response Patients - Management confirmed that the patient with complete response had been on study treatment for nine months before the response was observed [118] Question: Enrollment Plans for Doublet Dose Expansion Cohorts - The company plans to enroll up to 20 patients in the dual combination expansion cohorts, which will include a more significant number of patients across various tumor types compared to the monotherapy expansion [122]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________ ____________________________________ ___________________________________________________________ ________________________________________________ ________________________________________________ FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 ...

compugen CORPORATE OVERVIEW November 2020 SAFE HARBOR STATEMENT 2 This presentation contains "forward-looking statements" within the meaning of the the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of terminology such as "will," "may," "expects," "anticipates," "believes," "potential," "plan," "goal," "estimate," "likely," "should," and ...

Start Time: 08:30 January 1, 0000 9:25 AM ET Â Compugen Ltd. (NASDAQ:CGEN) Q3 2020 Earnings Conference Call November 05, 2020, 08:30 AM ET Company Participants Anat Cohen-Dayag - President and CEO Henry Adewoye - SVP and CMO Ari Krashin - CFO and COO Eran Ophir - VP, Research and Drug Discovery Elana Holzman - Director, IR and Corporate Communications Conference Call Participants Bonnie Quach - Stifel Daina Graybosch - SVB Leerink Mark Breidenbach - Oppenheimer Allen Donne - Truist Securities Justin Walsh - ...

Compugen Ltd (NASDAQ:CGEN) Q2 2020 Earnings Conference Call July 30, 2020 8:30 AM ET Company Participants Elana Holzman - Investor Relations Anat Dayag - CEO Henry Adewoye - Chief Medical Officer Ari Krashin - CFO and COO Eran Ophir - VP Research and Drug Discovery Conference Call Participants Stephen Willey - Stifel Daina Graybosch - SVB Leerink Matthew Biegler - Oppenheimer Asthika Goonewardene - SunTrust Colin White - Jefferies Justin Walsh - JMP Securities Tony Butler - Roth Capital Operator Ladies and ...

compugen CORPORATE OVERVIEW May 2020 SAFE HARBOR STATEMENT 2 This presentation contains "forward-looking statements" within the meaning of the the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of terminology such as "will," "may," "expects," "anticipates," "believes," "potential," "plan," "goal," "estimate," "likely," "should," and "int ...

Compugen Ltd. (NASDAQ:CGEN) Q1 2020 Earnings Conference Call May 6, 2020 8:30 AM ET Company Participants Elana Holzman - Director of IR and Corporate Communications Anat Cohen-Dayag - President and CEO Henry Adewoye - Chief Medical Officer Ari Krashin - CFO and COO Conference Call Participants Colin White - Jefferies Operator Ladies and gentlemen, thank you for standing by. Welcome to Compugen's First Quarter 2020 Results Conference Call. At this time, all participants are in a listen-only mode. An audio we ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________________________________________ ____________________________________ ___________________________________________________________________ ________________________________________________ ________________________________________________ FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ...